Alkem Laboratories Sees Sharp Open Interest Surge Amid Volatile Trading

Open Interest and Volume Dynamics

On the latest trading day, Alkem Laboratories recorded an open interest (OI) of 19,769 contracts in its futures and options, marking a substantial increase of 4,539 contracts or 29.8% compared to the previous day’s OI of 15,230. This surge in OI was accompanied by a total volume of 43,377 contracts, indicating robust participation in the derivatives market. The futures segment alone accounted for a value of approximately ₹35,927.64 lakhs, while the options segment’s notional value stood at an extraordinary ₹27,441.70 crores, culminating in a combined derivatives turnover of ₹40,128.49 lakhs.

The underlying stock price closed at ₹5,473, having experienced a sharp intraday decline to a low of ₹5,331.5, down 9.18%. The weighted average price of traded contracts clustered near the day’s low, signalling that most volume was executed at depressed price levels. This pattern often reflects bearish sentiment or aggressive short positioning by market participants.

Price Performance and Market Context

Alkem Laboratories underperformed its Pharmaceuticals & Biotechnology sector by a wide margin, falling 7.97% on the day compared to the sector’s modest 0.87% decline. The stock has now recorded losses for two consecutive sessions, with cumulative returns down 8.87% over this period. Intraday volatility was elevated at 5.44%, underscoring the heightened uncertainty and rapid price swings.

Technically, the stock remains above its 200-day moving average, a long-term support indicator, but trades below its 5-day, 20-day, 50-day, and 100-day moving averages. This mixed technical picture suggests that while the long-term trend remains intact, short- and medium-term momentum has weakened considerably.

Investor participation, measured by delivery volume, has also diminished sharply. On 12 Feb, delivery volume was 27,470 shares, down 58.56% from the five-day average, indicating reduced conviction among long-term holders amid the recent price weakness.

Interpreting the Open Interest Surge

The near 30% jump in open interest amid falling prices suggests that fresh positions are being established rather than existing ones being closed. This typically indicates that traders are either initiating new short positions or hedging existing long exposure. Given the stock’s sharp decline and volume concentration near lows, the evidence points towards increased bearish bets.

However, the sizeable open interest also reflects growing interest from institutional and retail participants in the derivatives market, possibly anticipating further directional moves. The large notional value in options contracts hints at complex strategies, including protective puts or speculative calls, which could moderate outright directional risk.

Market Positioning and Sentiment

Alkem Laboratories’ Mojo Score currently stands at 62.0, with a Mojo Grade of Hold, downgraded from Buy on 1 Dec 2025. This downgrade reflects a reassessment of the company’s near-term prospects amid sector headwinds and valuation pressures. The market cap grade remains at 2, consistent with its mid-cap status and liquidity profile.

The stock’s liquidity remains adequate for sizeable trades, with a 2% threshold of the five-day average traded value supporting trade sizes up to ₹1.2 crore. This ensures that institutional investors can enter or exit positions without excessive market impact, which is crucial during volatile phases.

Sector and Broader Market Comparison

While Alkem Laboratories has underperformed both its sector and the broader Sensex, which declined 1.14% on the day, the magnitude of its fall and open interest activity is notable. The Pharmaceuticals & Biotechnology sector has generally been resilient, supported by steady demand and innovation pipelines. The stock’s relative weakness may be attributed to company-specific factors such as earnings concerns, regulatory developments, or profit booking after recent gains.

Investors should monitor upcoming quarterly results and sector news closely, as these will likely influence the stock’s trajectory and derivatives positioning in the near term.

Investor Takeaways and Outlook

For investors and traders, the sharp rise in open interest combined with the stock’s recent price weakness signals caution. The derivatives market activity suggests that participants are positioning for further downside or increased volatility in the near term. Those holding long positions may consider protective strategies such as buying puts or tightening stop-loss levels.

Conversely, speculative traders might find opportunities in the heightened volatility and volume, employing option spreads or futures strategies to capitalise on directional moves or volatility spikes.

Given the downgrade to a Hold rating and the current technical setup, a conservative approach is advisable until clearer signals emerge from earnings or sector developments. Monitoring open interest trends alongside price action will remain critical to gauge evolving market sentiment.

Summary

Alkem Laboratories Ltd’s derivatives market has seen a pronounced increase in open interest, reflecting active repositioning amid a volatile and declining stock price. The surge in OI by nearly 30% alongside heavy volume near intraday lows points to growing bearish sentiment and complex hedging activity. While the stock remains above its long-term moving average, short-term momentum has weakened, and investor participation has declined. The downgrade to Hold and the stock’s underperformance relative to its sector and the Sensex underscore the need for caution. Market participants should closely watch upcoming corporate developments and derivatives positioning to navigate this evolving landscape effectively.

Unlock special upgrade rates for a limited period. Start Saving Now →